1254100-76-9

Upstream product

• 1254102-02-7 3-[3-({[(1-methylpiperidin-4-yl)oxy]carbonyl}amino)-4-phenylphenyl]propionate hydrochloride 
• 1254102-16-3 tert-butyl 3-(3-amino-4-phenylphenyl)propionate 
• 1254102-15-2 tert-butyl trans-3-(3-nitro-4-phenylphenyl)acrylate 
• 1254102-14-1 tert-butyl trans-3-(4-bromo-3-nitrophenyl)acrylate 
• 623-04-1 4-aminobenzenemethanol 
• 163596-75-6 4-bromo-3-nitrobenzaldehyde 
• 131230-76-7 4-[(tert-butyldimethylsilyloxy)methyl]aniline 
• 1254101-36-4 1-methylpiperidin-4-yl N-{5-[2-({4-[(tert-butyldimethylsilanoyloxy)methyl]phenyl}carbamoyl)ethyl]-2-phenylphenyl}carbamate 

Downstream Products

• 1254099-87-0 4-({[5-(2-{[4-(hydroxymethyl)phenyl]carbamoyl}ethyl)-2-phenylphenyl]carbamoyl}oxy)-1,1-dimethylpiperidin-1-iumiodide 
• 1254097-58-9 4-({[5-(2-{[4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)phenyl]carbamoyl}ethyl)-2-phenylphenyl]carbamoyl}oxy)-1,1-dimethylpiperidin-1-ium trifluoroacetate 
• 1254099-19-8 C₃₀H₃₄N₃O₄⁽¹⁺⁾*I^(1-) 

Relevant academic research and scientific papers

QUATERNARY AMMONIUM SALT COMPOUNDS

[Problem] The object of the present invention is to provide a novel compound having 132 adrenergic receptor agonist activity and muscarinic receptor antagonist activity. [Means for Solving the Problem] The present invention is a quaternary ammonium salt compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, with superior β32 adrenergic receptor agonist activity and muscarinic receptor antagonist activity.